Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients
…, DP Speert, SM Moskowitz… - Proceedings of the …, 2006 - National Acad Sciences
In many human infections, hosts and pathogens coexist for years or decades. Important
examples include HIV, herpes viruses, tuberculosis, leprosy, and malaria. With the exception of …
examples include HIV, herpes viruses, tuberculosis, leprosy, and malaria. With the exception of …
[HTML][HTML] Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele
…, CM McKee, SM Moskowitz… - … England Journal of …, 2019 - Mass Medical Soc
Background Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis
transmembrane conductance regulator (CFTR) protein, and nearly 90% of patients have at …
transmembrane conductance regulator (CFTR) protein, and nearly 90% of patients have at …
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double …
…, CM McKee, G Marigowda, SM Moskowitz… - The Lancet, 2019 - thelancet.com
Background Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct
the basic defect caused by CFTR mutations. Improvements in health outcomes have been …
the basic defect caused by CFTR mutations. Improvements in health outcomes have been …
[HTML][HTML] VX-445–tezacaftor–ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles
…, E Tullis, CM McKee, SM Moskowitz… - New england journal …, 2018 - Mass Medical Soc
Background VX-445 is a next-generation cystic fibrosis transmembrane conductance regulator
(CFTR) corrector designed to restore Phe508del CFTR protein function in patients with …
(CFTR) corrector designed to restore Phe508del CFTR protein function in patients with …
PmrAB, a Two-Component Regulatory System of Pseudomonas aeruginosa That Modulates Resistance to Cationic Antimicrobial Peptides and Addition of …
SM Moskowitz, RK Ernst, SI Miller - Journal of bacteriology, 2004 - Am Soc Microbiol
Spontaneous polymyxin-resistant mutants of Pseudomonas aeruginosa were isolated. The
mutations responsible for this phenotype were mapped to a two-component signal …
mutations responsible for this phenotype were mapped to a two-component signal …
Clinically Feasible Biofilm Susceptibility Assay for Isolates of Pseudomonas aeruginosa from Patients with Cystic Fibrosis
SM Moskowitz, JM Foster, J Emerson… - Journal of clinical …, 2004 - Am Soc Microbiol
Pseudomonas aeruginosa is the predominant cause of chronic airway infection in cystic
fibrosis (CF). CF airway isolates are often tested for antibiotic susceptibility but are rarely …
fibrosis (CF). CF airway isolates are often tested for antibiotic susceptibility but are rarely …
[HTML][HTML] Triple Therapy for Cystic Fibrosis Phe508del–Gating and –Residual Function Genotypes
…, N Ahluwalia, LS Jun, SM Moskowitz… - … England Journal of …, 2021 - Mass Medical Soc
Background Elexacaftor–tezacaftor–ivacaftor is a small-molecule cystic fibrosis transmembrane
conductance regulator (CFTR) modulator regimen shown to be efficacious in patients …
conductance regulator (CFTR) modulator regimen shown to be efficacious in patients …
[HTML][HTML] VX-659–tezacaftor–ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles
JC Davies, SM Moskowitz, C Brown… - New england journal …, 2018 - Mass Medical Soc
Background The next-generation cystic fibrosis transmembrane conductance regulator (CFTR)
corrector VX-659, in triple combination with tezacaftor and ivacaftor (VX-659–tezacaftor–…
corrector VX-659, in triple combination with tezacaftor and ivacaftor (VX-659–tezacaftor–…
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele
…, N Ahluwalia, C Chu, T Ho, SM Moskowitz… - American journal of …, 2021 - atsjournals.org
Rationale: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be efficacious and
safe in patients ≥12 years of age with cystic fibrosis and at least one F508del-CFTR (cystic …
safe in patients ≥12 years of age with cystic fibrosis and at least one F508del-CFTR (cystic …
[PDF][PDF] Carbon sources tune antibiotic susceptibility in Pseudomonas aeruginosa via tricarboxylic acid cycle control
…, MA Lobritz, J Park, SH Kim, SM Moskowitz… - Cell chemical …, 2017 - cell.com
Metabolically dormant bacteria present a critical challenge to effective antimicrobial therapy
because these bacteria are genetically susceptible to antibiotic treatment but phenotypically …
because these bacteria are genetically susceptible to antibiotic treatment but phenotypically …